ATRC AtriCure, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ATRC matters now
AtriCure, Inc. (ATRC) is a US stock in Healthcare. The latest InvestLog snapshot shows $34.28 with -0.81% on the session and $1.74B in market capitalization; recent performance reads 1-month +0.00% and YTD -27.20%.
The latest financial table shown here is Q1 2026, with revenue of $141.2M, net income of $108.0K, and EPS of $0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 3.7%.
The latest indexable market news headline is "AtriCure to Announce Second Quarter 2026 Financial Results" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $55.00; recent insider activity includes Prange Karen filing S-Sale; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.83
P/S
2.64
EV/EBITDA
56.16
DCF Value
$-3.03
FCF Yield
3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.5%
Operating Margin
-0.4%
Net Margin
-0.8%
ROE
-1.0%
ROA
-0.7%
ROIC
-0.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $141.2M | $108.0K | $0.00 |
| Q4 2025 | $140.5M | $1.8M | $0.04 |
| FY 2025 | $534.5M | $-11.4M | $-0.24 |
| Q3 2025 | $134.3M | $-267.0K | $-0.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$51.33
Target (Median)
$55.00
Target Range
$44.00 - $55.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.26
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.